[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 753
6. Ciocca V, Bombonati A, Palazzo JP, Schulz S, Waldman SA: Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms. Histopathology; 2009 Aug;55(2):182-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms.
  • AIMS: The aim was to assess the value of GCC in distinguishing primary ovarian mucinous neoplasms from metastatic mucinous adenocarcinomas with ovarian involvement.
  • METHODS AND RESULTS: Fifty ovarian tumours: 27 primary ovarian mucinous neoplasms (seven cystadenomas, 10 borderline tumours and 10 cystadenocarcinomas) and 23 metastatic mucinous adenocarcinomas with ovarian involvement [13 colorectal adenocarcinomas, four gastric adenocarcinomas, six appendiceal mucinous tumours (four adenocarcinomas, one with neuroendocrine features, and two appendiceal mucinous cystadenomas)] were studied.
  • For primary ovarian mucinous neoplasms, 25 of 27 were negative for GCC.
  • Twelve of 13 cases of colorectal adenocarcinoma (except for one neuroendocrine adenocarcinoma) were positive for GCC.
  • Three of four appendiceal mucinous adenocarcinomas were positive for GCC in both the primary and metastatic tumours (except for one neuroendocrine adenocarcinoma).
  • Of four cases of gastric adenocarcinoma with ovarian involvement, only one (primary tumour) exhibited focal GCC staining.
  • CONCLUSIONS: GCC is a useful marker for differentiating between primary and secondary ovarian mucinous neoplasms.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2000 Jul;119(1):89-96 [10889158.001]
  • [Cites] Mod Pathol. 2006 Nov;19(11):1421-8 [16980943.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5151-7 [11016642.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7846-51 [11438734.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):281-92 [12604884.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2695-9 [12594332.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):985-93 [12826891.001]
  • [Cites] Virchows Arch. 2003 Dec;443(6):782-6 [14576939.001]
  • [Cites] Am J Physiol. 1983 Oct;245(4):G492-8 [6312810.001]
  • [Cites] Cell. 1990 Nov 30;63(5):941-8 [1701694.001]
  • [Cites] J Biol Chem. 1991 Sep 25;266(27):17912-8 [1680854.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):947-51 [1346555.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10464-8 [7902563.001]
  • [Cites] J Anat. 1994 Apr;184 ( Pt 2):407-17 [8014132.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14827-32 [8962140.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1144-55 [9331286.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):617-35 [10366144.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):19-25 [15389251.001]
  • [Cites] Hum Pathol. 2005 Feb;36(2):170-9 [15754294.001]
  • [Cites] Int J Gynecol Pathol. 2006 Jan;25(1):83-9 [16306790.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):97-105 [16294196.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1130-9 [16931958.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):962-72 [11007036.001]
  • (PMID = 19694825.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA75123; United States / NCI NIH HHS / CA / R01 CA075123-04; United States / NCI NIH HHS / CA / R01 CA095026-04; United States / NCI NIH HHS / CA / R01 CA095026; United States / NCI NIH HHS / CA / CA95026; United States / NCI NIH HHS / CA / R01 CA075123
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Peptide; EC 4.6.1.2 / Guanylate Cyclase; EC 4.6.1.2 / Receptors, Guanylate Cyclase-Coupled; EC 4.6.1.2 / enterotoxin receptor
  • [Other-IDs] NLM/ NIHMS309367; NLM/ PMC3140017
  •  go-up   go-down


7. Dahlstedt E, Collins HA, Balaz M, Kuimova MK, Khurana M, Wilson BC, Phillips D, Anderson HL: One- and two-photon activated phototoxicity of conjugated porphyrin dimers with high two-photon absorption cross sections. Org Biomol Chem; 2009 Mar 7;7(5):897-904
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These dimers demonstrate high one-photon PDT efficacy against a human ovarian adenocarcinoma cell line (SK-OV-3) and exhibit no significant dark-toxicity at concentrations of up to 20 microM.
  • [MeSH-minor] Cell Line, Tumor. Dimerization. Female. Humans. Infrared Rays. Ovarian Neoplasms / therapy. Photons. Photosensitizing Agents / pharmacology. Solubility

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19225672.001).
  • [ISSN] 1477-0539
  • [Journal-full-title] Organic & biomolecular chemistry
  • [ISO-abbreviation] Org. Biomol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


8. Karlberg S, Lipsanen-Nyman M, Lassus H, Kallijärvi J, Lehesjoki AE, Butzow R: Gynecological tumors in Mulibrey nanism and role for RING finger protein TRIM37 in the pathogenesis of ovarian fibrothecomas. Mod Pathol; 2009 Apr;22(4):570-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gynecological tumors in Mulibrey nanism and role for RING finger protein TRIM37 in the pathogenesis of ovarian fibrothecomas.
  • More than half of female patients with Mulibrey nanism develop benign mesenchymal tumors of ovarian sex cord-stromal origin.
  • In addition to tumors of the fibrothecoma group, 18% (4/22) of the patients were observed with epithelial neoplasias, including 2 ovarian adenofibromas, 1 ovarian poorly differentiated adenocarcinoma and 1 endometrial adenocarcinoma.
  • TRIM37del2 was also found in normal ovary but in a proportion of sporadic fibrothecomas, the TRIM37del2:TRIM37 ratio was increased.
  • In normal ovary, TRIM37 was localized in the cytoplasm of stromal cells, especially theca cells surrounding developing follicles.
  • In conclusion, inherited biallelic inactivation of TRIM37 (Mulibrey nanism) predisposes to both mesenchymal and epithelial ovarian tumors and dysregulation of TRIM37 may also be involved in the pathogenesis of sporadic fibrothecomas.
  • [MeSH-major] Mulibrey Nanism / complications. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Ovarian Neoplasms / genetics. Thecoma / genetics

  • Genetic Alliance. consumer health - Mulibrey Nanism.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329943.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / TRIM37 protein, human
  •  go-up   go-down


9. Busquets M, Gonzalez-Bosquet E, Muchart J, Rovira C, Laïlla JM: Granulosa cell tumor and endometrial cancer: a case report and review of the literature. Eur J Gynaecol Oncol; 2010;31(5):575-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulosa cell tumor and endometrial cancer: a case report and review of the literature.
  • Granulosa cell tumors (GCTs) of the ovary are an uncommon type of ovarian cancer, representing only 2-5%.
  • As a consequence, this neoplasia can be diagnosed either by common ovarian cancer symptoms or endometrial pathologies due to an estrogenic effect.
  • Once endometrial cancer was diagnosed and subsequently staged, an ovarian mass was detected.
  • We report an atypical case of ovarian cancer with the aim of reviewing the clinical features of GCT, as well as its prognosis, treatment and follow-up recommendations, according to the available literature.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Granulosa Cell Tumor / pathology. Neoplasms, Multiple Primary. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21061806.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


10. Köbel M: [Ovarian carcinoma. Do the subtypes reflect different diseases?]. Pathologe; 2008 Nov;29 Suppl 2:160-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian carcinoma. Do the subtypes reflect different diseases?].
  • Lack of therapeutic options and poor reproducibility of histopathological subtypes have been the reasons that ovarian carcinomas are currently treated as monolithic entity.
  • [MeSH-major] Ovarian Neoplasms / classification. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / classification. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / classification. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / classification. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. DNA Mutational Analysis. Diagnosis, Differential. Female. Genetic Markers / genetics. Humans. Observer Variation. Ovary / pathology. Practice Guidelines as Topic. Prognosis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1998 Jul;70(1):2-12 [9698465.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):407-11 [12352190.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14 (1):89-96 [18172257.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):189-93 [11161858.001]
  • [Cites] Onkologie. 2002 Jun;25(3):240-7 [12119458.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1369-74 [16641903.001]
  • [Cites] APMIS. 1991 Apr;99(4):353-8 [2036219.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):89-94 [15385115.001]
  • [Cites] BMC Cancer. 2008 Jan 22;8:17 [18208621.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1239-51 [18602670.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Lancet. 2003 Sep 13;362(9387):869-75 [13678974.001]
  • [Cites] Gynecol Oncol. 2008 Apr;109(1):129-39 [18234305.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1168-74 [17667538.001]
  • [Cites] Breast Cancer Res Treat. 2008 Dec;112(3):453-9 [18193353.001]
  • [Cites] Am J Surg Pathol. 2009 Jan;33(1):14-21 [18830127.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):283-90 [12525520.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] Am J Pathol. 1977 Jun;87(3):686-720 [194486.001]
  • [Cites] Int J Gynecol Pathol. 2000 Apr;19(2):158-63 [10782413.001]
  • [Cites] Mod Pathol. 2006 Apr;19(4):581-7 [16554733.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):453-63 [15087664.001]
  • [Cites] Neoplasia. 2008 Sep;10(9):1021-7 [18714364.001]
  • [Cites] PLoS One. 2007 Nov 07;2(11):e1138 [17987122.001]
  • [Cites] Histopathology. 2006 Jan;48(2):149-56 [16405663.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):917-21 [15829967.001]
  • [Cites] Arch Pathol Lab Med. 1991 Apr;115(4):377-81 [1672813.001]
  • (PMID = 18709371.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


11. Takano M, Sasaki N, Kita T, Kudoh K, Fujii K, Yoshikawa T, Kato M, Hirata J, Furuya K, Tsuda H, Kikuchi Y: Survival analysis of ovarian clear cell carcinoma confined to the ovary with or without comprehensive surgical staging. Oncol Rep; 2008 May;19(5):1259-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival analysis of ovarian clear cell carcinoma confined to the ovary with or without comprehensive surgical staging.
  • Pure-type clear cell carcinoma (CCC) has been recognized as a distinct subtype of ovarian cancer, showing a resistance to chemotherapy and resulting in poor prognosis.
  • Our aim was to evaluate the effects of complete surgical procedures followed by adjuvant chemotherapy for CCC patients whose tumors were confined to the ovary (pT1M0).
  • The present study indicates that we should accomplish complete surgical staging procedures for CCC confined to the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / mortality. Neoplasm Staging. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425385.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


12. McCluggage WG, Hurrell DP, Kennedy K: Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. Am J Surg Pathol; 2010 May;34(5):735-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases.
  • A variety of other neoplasms rarely metastasize to the cervix and, in most cases, the diagnosis is straightforward because of a combination of clinical and pathologic parameters, common features of metastatic carcinoma within the cervix including predominant involvement of the deep stroma, absence of surface involvement and of an in situ component, and prominent lymphovascular permeation.
  • We describe 6 cases of metastatic adenocarcinoma involving the cervix with superficial "mucosal" involvement mimicking primary cervical adenocarcinoma or adenocarcinoma in situ.
  • In 5 cases, the primary adenocarcinoma was in the ovary or peritoneum and was of serous (4 cases) or clear-cell (1 case) type.
  • In the other case, the primary neoplasm was in the pancreas and this was initially interpreted as a primary cervical adenocarcinoma.
  • In the cases of primary ovarian or peritoneal carcinoma, the mucosal tumor within the cervix, which was discovered at the same time as the ovarian or peritoneal neoplasm, raised the possibility of synchronous independent lesions or metastasis from the cervix to the ovary or peritoneum.
  • In those cases with an ovarian or peritoneal primary, the likely pathogenesis of the cervical involvement is transtubal and intrauterine spread.
  • It is important for the pathologist to be aware of the possibility of cervical mucosal metastasis to avoid an erroneous diagnosis of a primary cervical adenocarcinoma or adenocarcinoma in situ.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged


13. Tamada Y, Takeuchi H, Suzuki N, Susumu N, Aoki D, Irimura T: Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary. Cancer Sci; 2007 Oct;98(10):1586-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary.
  • A monoclonal antibody (mAb) MY.1E12 was applied to detect MUC1 with sialylated glycans in a total of 55 formalin-fixed, paraffin-embedded surgical specimens of ovarian clear cell adenocarcinomas.
  • To examine the role of MUC1 in ovarian clear cell carcinomas, two cDNA encoding MUC1 were transfected into ES-2 ovarian clear cell carcinoma cells.
  • The results indicate that MUC1 expressed on ovarian clear cell carcinoma cells is causally involved in the malignant behavior.
  • [MeSH-major] Adenocarcinoma, Clear Cell / immunology. Antibodies, Monoclonal. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mucin-1 / immunology. Ovarian Neoplasms / immunology. Sialic Acids / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17711507.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Mucin-1; 0 / Sialic Acids; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


1
Advertisement
4. Nishimura N, Hachisuga T, Nabeshima K, Kawarabayashi T: Synchronous endometrial and ovarian carcinomas: analysis of genetic relationship of the tumors. Int J Oncol; 2005 Dec;27(6):1519-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous endometrial and ovarian carcinomas: analysis of genetic relationship of the tumors.
  • Simultaneous carcinomas of the endometrium and ovary may represent a diagnostic dilemma and the clinical management of such cases may be problematic.
  • In this study, in addition to the clinicopatho-logic classification, we assessed tumor cell clonality in 13 cases with synchronous endometrial and ovarian endometrioid adenocarcinomas using PCR-based microsatellite analysis of microdissected archival tissues for loss of heterozygosity (LOH) and microsatellite instability (MSI).
  • All paired endometrial and ovarian tumors demonstrated either MSI or/and LOH except for 1 case, and therefore the microsatellite analysis was informative in 92.3% of the cases.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Loss of Heterozygosity. Microsatellite Repeats / genetics. Middle Aged. Neoplasm Metastasis / genetics. Neoplasm Metastasis / pathology. Neoplasms, Multiple Primary / genetics. Neoplasms, Multiple Primary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273207.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


15. Devalapally H, Shenoy D, Little S, Langer R, Amiji M: Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Cancer Chemother Pharmacol; 2007 Mar;59(4):477-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model.
  • PURPOSE: The objective of this study was to evaluate the anti-tumor efficacy and lack of systemic toxicity of paclitaxel when administered in pH-sensitive poly(ethylene oxide) (PEO)-modified poly(beta-amino ester) (PbAE) nanoparticles in mice bearing human ovarian adenocarcinoma (SKOV-3) xenograft.
  • [MeSH-major] Drug Delivery Systems. Nanoparticles. Ovarian Neoplasms / drug therapy. Paclitaxel / administration & dosage. Polyesters / administration & dosage

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16862429.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA095522; United States / NCI NIH HHS / CA / R01-CA119617
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Polyesters; 24980-41-4 / polycaprolactone; 30IQX730WE / Polyethylene Glycols; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


16. Husein-ElAhmed H, Aneiros-Fernandez J, Arias-Santiago S, Naranjo-Sintes R: Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma. Int J Dermatol; 2010 Sep;49(9):1045-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Ovarian Neoplasms / pathology. Sister Mary Joseph's Nodule / secondary. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20883267.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vimentin; 0 / WT1 Proteins; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; BG3F62OND5 / Carboplatin; EC 3.4.24.11 / Neprilysin; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Medeiros F, Bell DA: Pseudoneoplastic lesions of the female genital tract. Arch Pathol Lab Med; 2010 Mar;134(3):393-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several of the more common pseudoneoplastic lesions are discussed in this article, including microglandular hyperplasia of the cervix mimicking well-differentiated endometrial adenocarcinoma, reactive epithelial changes in the fallopian tubes mimicking adenocarcinoma or carcinoma in situ, and pregnancy changes in the ovary including pregnancy luteoma and large solitary luteinized follicular cyst of pregnancy and puerperium that may mimic ovarian neoplasms.
  • Awareness of the features of such lesions will aid in their correct diagnosis and prevent overtreatment of benign processes.
  • [MeSH-major] Genital Diseases, Female / diagnosis. Granuloma, Plasma Cell / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Genital Neoplasms, Female / classification. Genital Neoplasms, Female / diagnosis. Humans. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20196667.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 76
  •  go-up   go-down


18. Babu MR, Haji AG, Chitrathara K, Vijaykumar DK, Samanta J, Hiran KR: Primary transitional cell carcinoma of the fallopian tube in a premenopausal woman: A case report and review of literature. Indian J Med Paediatr Oncol; 2009 Jan;30(1):35-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In view of the elevated CA-125 and imaging findings suggestive of ovarian mass, she underwent staging laparotomy.
  • Review of available literature suggested that the primary transitional cell carcinoma is probably less aggressive compared to classical adenocarcinoma of the fallopian tube, and it has to be distinguished from the recently recognized entity, parafallopian tube transitional cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Jan;80(1):16-20 [11136563.001]
  • [Cites] Gynecol Oncol. 1987 Mar;26(3):305-13 [3557196.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):367-79 [10053109.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):469-75 [9887253.001]
  • [Cites] Cytojournal. 2005;2:20 [16336674.001]
  • [Cites] Oncologist. 2006 Sep;11(8):902-12 [16951394.001]
  • [Cites] Surg Clin North Am. 1978 Feb;58(1):121-9 [644422.001]
  • [Cites] Gynecol Oncol. 2002 Sep;86(3):379-83 [12217766.001]
  • [Cites] Cancer. 1993 Oct 15;72(8):2447-56 [8402462.001]
  • (PMID = 20668606.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2902214
  • [Keywords] NOTNLM ; Carcinoma ovary / fallopian tube / transitional cell carcinoma
  •  go-up   go-down


19. Hewitt MJ, Hall GD, Wilkinson N, Perren TJ, Lane G, Spencer JA: Image-guided biopsy in women with breast cancer presenting with peritoneal carcinomatosis. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:108-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image-guided biopsy in women with breast cancer presenting with peritoneal carcinomatosis.
  • When women with a history of breast cancer present with peritoneal carcinomatosis, the differential diagnosis lies between recurrent breast cancer or a new primary tumor.
  • This scenario is of particular relevance to women with a BRCA gene mutation, who have a genetic predisposition to develop second primary tumors of the ovary, fallopian tube, and peritoneum.
  • We describe the use of image-guided core biopsy as an alternative to laparoscopy or exploratory laparotomy in providing minimally invasive diagnosis in this increasingly common clinical dilemma.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Mixed Tumor, Mullerian / pathology. Peritoneal Neoplasms / pathology. Peritoneum / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515576.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Pozdnyakova O, Hoang MM, Dresser KA, Mahalingam M: Prognostic value of E-cadherin, beta-catenin, CD44v6, and HER2/neu in metastatic cutaneous adenocarcinoma. Arch Pathol Lab Med; 2009 Aug;133(8):1285-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of E-cadherin, beta-catenin, CD44v6, and HER2/neu in metastatic cutaneous adenocarcinoma.
  • CONTEXT: Our recent experience with a patient developing cutaneous metastases within 3 months of diagnosis of esophageal adenocarcinoma suggests that altered expression of the cellular adhesion molecules, E-cadherin and CD44v6, may have had a role to play in the rapid onset of metastases.
  • DESIGN: E-cadherin, beta-catenin, CD44v6, and HER2/neu immunohistochemical stains were performed on archival materials of metastatic adenocarcinoma to the skin from 27 patients and the available corresponding primary tumors in 10 patients.
  • The primary sites included breast (n = 10; 37%), gastrointestinal tract (n = 10; 37%), ovary (n = 1; 4%), thyroid (n = 2; 7%), lung (n = 1; 4%), and unknown primary (n = 3; 11%).
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Esophageal Neoplasms / metabolism. Neoplasm Proteins / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653727.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Cadherins; 0 / Neoplasm Proteins; 0 / beta Catenin; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


21. Kim KY, Kim SU, Leung PC, Jeung EB, Choi KC: Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth. Cancer Sci; 2010 Apr;101(4):955-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth.
  • In the present study, we evaluated whether these GESTECs were capable of migrating to human ovarian cancer cells and examined the potential therapeutic efficacy of the gene-directed enzyme prodrug therapy against ovarian cancer cells in vitro.
  • A modified transwell migration assay was performed to determine the migratory capacity of GESTECs to ovarian cancer cells.
  • GESTECs (HB1.F3.CD or HB1.F3.CE cells) engineered to express a suicide gene (CD or CE) selectively migrated toward ovarian cancer cells.
  • Treatment of human epithelial ovarian cancer cell line (SKOV-3, an ovarian adenocarcinoma derived from the ascites of an ovarian cancer patient) with the prodrugs 5-fluorocytosine (5-FC) or camptothecin-11 (CPT-11) in the presence of HB1.F3.CD or HB1.F3.CE cells resulted in the inhibition of ovarian cancer cell growth.
  • Based on the data presented herein, we suggest that GESTECs expressing CD/CE may have a potent advantage to selectively treat ovarian cancers.
  • [MeSH-major] Antimetabolites / pharmacology. Antineoplastic Agents, Phytogenic / pharmacology. Camptothecin / analogs & derivatives. Flucytosine / pharmacology. Genetic Therapy / methods. Ovarian Neoplasms / therapy. Prodrugs / pharmacology. Stem Cells

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. FLUCYTOSINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20704576.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites; 0 / Antineoplastic Agents, Phytogenic; 0 / Prodrugs; 7673326042 / irinotecan; D83282DT06 / Flucytosine; EC 3.5.4.1 / Cytosine Deaminase; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


22. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ: Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol; 2005 Jan;18(1):105-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma.
  • Although immunohistochemistry has proven to be valuable in the differentiation of epithelioid mesothelioma from pulmonary or metastatic adenocarcinoma, no single antibody has demonstrated absolute sensitivity or specificity in making this distinction.
  • Using immunohistochemical analysis with D2-40, a recently available monoclonal antibody that has been used as a lymphatic endothelial marker, we examined 53 cases of mesothelioma, 28 cases of reactive pleura, 30 cases of pulmonary adenocarcinoma, 35 cases of renal cell carcinoma, 26 cases of ovarian serous carcinoma, 16 cases of invasive breast carcinoma, 11 cases of prostatic adenocarcinoma, and seven cases of urothelial carcinoma.
  • In addition, immunohistochemistry using calretinin, cytokeratin 5/6, and WT1 was performed on all cases of mesothelioma, pulmonary adenocarcinoma, ovarian serous carcinoma, and renal cell carcinoma.
  • Predominantly, membranous D2-40 immunoreactivity was present in 51 of 53 (96%) mesotheliomas, 27 of 28 (96%) cases of reactive pleura, and 17 of 26 (65%) ovarian serous carcinomas; membranous staining was not seen in any other tumors examined.
  • We conclude that D2-40 immunoreactivity is sensitive for cells of mesothelial origin, and may be useful in the differential diagnosis of epithelioid malignant mesothelioma vs adenocarcinoma.
  • [MeSH-major] Antibodies, Monoclonal. Biomarkers, Tumor. Mesothelioma / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15389250.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40; 0 / oncofetal antigens
  •  go-up   go-down


23. Solár P, Horváth V, Kleban J, Koval' J, Solárová Z, Kozubík A, Fedorocko P: Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin. Neoplasma; 2007;54(2):127-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin.
  • Ovarian carcinoma is the leading cause of death among gynecological neoplasms in the world.
  • The chemoresistance is a major obstacle in the effective treatment of ovarian and other cancers.
  • We evaluated the effects of Hsp90 inhibitor geldanamycin (GEL) alone and in combination with cisplatin in cisplatin resistant ovarian adenocarcinoma cell line.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Benzoquinones / pharmacology. Cisplatin / pharmacology. Drug Resistance, Neoplasm. Enzyme Inhibitors / pharmacology. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Lactams, Macrocyclic / pharmacology. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Blotting, Western. Cell Cycle / drug effects. Cell Proliferation / drug effects. Female. Humans. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319785.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / Enzyme Inhibitors; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; Q20Q21Q62J / Cisplatin; Z3K3VJ16KU / geldanamycin
  •  go-up   go-down


24. Batra S, Singh M, Wynn JS: An unusual case of primary fallopian tube carcinoma in pregnancy. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:365-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A staging laparotomy in the postnatal period showed no spread of tumor, and in view of her age and desire for further pregnancies, her uterus and other ovary and tube were conserved.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Fallopian Tube Neoplasms / surgery. Pregnancy Complications, Neoplastic

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515625.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Roth LM, Miller AW 3rd, Talerman A: Typical thyroid-type carcinoma arising in struma ovarii: a report of 4 cases and review of the literature. Int J Gynecol Pathol; 2008 Oct;27(4):496-506
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Upon review of the literature, papillary carcinoma and follicular carcinoma are the most frequent types of malignancy to occur in ovarian struma; other forms of thyroid carcinoma occur only rarely.
  • In reference to follicular carcinoma, invasion into the surrounding ovarian tissue, vascular invasion, or metastasis is evidence of malignancy.
  • Histological malignancy in a struma does not necessarily equate with biological malignancy, and the majority of thyroid-type carcinomas do not spread beyond the ovary.
  • Occasionally, metastases of ovarian struma have an innocuous histological appearance, and such cases are referred to as highly differentiated follicular carcinoma of ovarian origin (HDFCO).
  • Because its histological appearance resembles that of nonneoplastic thyroid, HDFCO characteristically cannot be diagnosed until the neoplasm spreads beyond the ovary.
  • In this article, we apply the term typical thyroid carcinoma to those forms of thyroid malignancy arising in ovarian struma that closely resemble the types described in the cervical thyroid gland to distinguish them from HDFCO.
  • Cases of thyroid-type carcinoma arising in the ovary sometimes lack evidence of preexisting struma.
  • Primary thyroid-type carcinoma must be distinguished from rare instances of ovarian metastases that originate in the cervical thyroid gland and the less differentiated forms from other ovarian neoplasms such as clear cell adenocarcinoma and tumors with an oxyphilic appearance.
  • In the differential diagnosis with other ovarian neoplasms, cases of thyroid-type carcinoma associated with strumal carcinoid should not be diagnosed as malignant strumal carcinoid because the latter diagnosis might lead to suboptimal therapy.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoid Tumor / pathology. Carcinoma, Papillary / pathology. Ovarian Neoplasms / pathology. Struma Ovarii / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753973.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K: Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res; 2007 Jul;168(1):1-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid cancer incidence in atomic bomb survivors: 1958-1998.
  • The analyses were based on 17,448 first primary cancers (including non-melanoma skin cancer) diagnosed from 1958 through 1998 among 105,427 cohort members with individual dose estimates who were alive and not known to have had cancer prior to 1958.
  • Radiation-associated relative risks and excess rates were considered for all solid cancers as a group, for 19 specific cancer sites or groups of sites, and for five histology groups.
  • It was estimated that, at age 70 after exposure at age 30, solid cancer rates increase by about 35% per Gy (90% CI 28%; 43%) for men and 58% per Gy (43%; 69%) for women.
  • Despite the decline in the ERR with attained age, excess absolute rates appeared to increase throughout the study period, providing further evidence that radiation-associated increases in cancer rates persist throughout life regardless of age at exposure.
  • Significant radiation-associated increases in risk were seen for most sites, including oral cavity, esophagus, stomach, colon, liver, lung, non-melanoma skin, breast, ovary, bladder, nervous system and thyroid.
  • However, there was emerging evidence from the present data that exposure as a child may increase risks of cancer of the body of the uterus.
  • Elevated risks were seen for all of the five broadly classified histological groups considered, including squamous cell carcinoma, adenocarcinoma, other epithelial cancers, sarcomas and other non-epithelial cancers.
  • Although the data were limited, there was a significant radiation-associated increase in the risk of cancer occurring in adolescence and young adulthood.
  • In view of the persisting increase in solid cancer risks, the LSS should continue to provide important new information on radiation exposure and solid cancer risks for at least another 15 to 20 years.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722996.001).
  • [ISSN] 0033-7587
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CP / N01-CP-31021; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


27. Blich M, Malkin L, Kapeliovich M: Malignant pericardial tamponade secondary to papillary serous adenocarcinoma of the ovary. Isr Med Assoc J; 2007 Apr;9(4):337-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial tamponade secondary to papillary serous adenocarcinoma of the ovary.
  • [MeSH-major] Cardiac Tamponade / etiology. Cystadenocarcinoma, Papillary / secondary. Mediastinal Neoplasms / secondary. Ovarian Neoplasms / pathology. Pericardium
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biopsy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Ovariectomy. Pericardiocentesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17491236.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


28. Hecht JL, Dolinski BM, Gardner HA, Violette SM, Weinreb PH: Overexpression of the alphavbeta6 integrin in endometrial cancer. Appl Immunohistochem Mol Morphol; 2008 Dec;16(6):543-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of the alphavbeta6 integrin in endometrial cancer.
  • The alpha(v)beta(6) integrin (alphavbeta6) has been shown to be up-regulated in adenocarcinoma of the breast, colon, stomach, and ovary, generally reflecting a more aggressive phenotype.
  • Expression in endometrial cancer has not been reported.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698261.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alphaV; 0 / Integrin beta Chains; 0 / integrin beta6
  •  go-up   go-down


29. Kusuda T, Shigemasa K, Arihiro K, Fujii T, Nagai N, Ohama K: Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep; 2005 Jun;13(6):1153-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
  • The aim of the present study was to examine mRNA expression levels of Th1 (TNF-alpha , IFN-gamma, and IL-12p40) and Th2 (IL-6 and IL-10) cytokines for any association with clinicopathological characteristics of epithelial ovarian cancer. mRNA was isolated, and cDNA prepared from 40 samples of epithelial ovarian cancers.
  • Tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) expression levels were significantly higher in serous adenocarcinoma than in non-serous adenocarcinoma (p<0.05), but with no difference between individual cytokine mRNA expression levels and clinical stage or histological grade.
  • Log-rank testing showed that high TNF-alpha mRNA expression (p=0.033) and the diameter of largest residual lesion at initial surgery (p=0.012) significantly correlate with longer survival in advanced stage (II/III/IV) ovarian carcinomas.
  • In examining all combinations of Th1/Th2 expression values, the most significant association was between high IFN-gamma.IL-12p40/IL-6 expression levels and better prognosis in advanced stage (II/III/IV) ovarian carcinomas (p=0.004).
  • In conclusion, Th1 and Th2 cytokines might play an important role in regulating the immune reaction in epithelial ovarian cancer cells.
  • IFN-gamma.IL-12p40/IL-6 expression may be a useful prognostic molecular marker for patients with advanced ovarian cancer.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Th1 Cells / metabolism. Th2 Cells / metabolism
  • [MeSH-minor] Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. DNA, Complementary / genetics. DNA, Complementary / metabolism. Female. Humans. Interferon-gamma / genetics. Interferon-gamma / metabolism. Interleukin-10 / genetics. Interleukin-10 / metabolism. Interleukin-12 / genetics. Interleukin-12 / metabolism. Interleukin-12 Subunit p40. Interleukin-6 / genetics. Interleukin-6 / metabolism. Ovary / metabolism. Ovary / pathology. Prognosis. Protein Subunits / genetics. Protein Subunits / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factor-alpha / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870936.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Interleukin-12 Subunit p40; 0 / Interleukin-6; 0 / Protein Subunits; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


30. Tada E, Toyomura K, Nakamura H, Sasaki H, Saito T, Kaneko M, Okuma Y, Murayama T: Activation of ceramidase and ceramide kinase by vanadate via a tyrosine kinase-mediated pathway. J Pharmacol Sci; 2010;114(4):420-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also we found that 1) treatment of NBD-ceramide-labeled cells (human lung adenocarcinoma A549 cells and Chinese hamster ovary cells) with Na(3)VO(4) increased the amount of NBD-C1P formed within 30 min, 2) the treatment increased production of NBD-caproic acid, a counterpart of sphingosine, by ceramidase within 2 h, 3) expression of ceramide kinase enhanced the Na(3)VO(4)-induced formation of NBD-C1P, and tyrosine kinase inhibitors (herbimycin and genistein) decreased the response, 4) the production of NBD-caproic acid in A549 cells was inhibited by genistein, and 5) the responses for 2 h after Na(3)VO(4) treatment were accompanied by a decrease in the production of NBD-sphingomyelin, not a loss of NBD-ceramide.

  • National BioResource Project. culture/stock collections - NBRP resources .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21127389.001).
  • [ISSN] 1347-8648
  • [Journal-full-title] Journal of pharmacological sciences
  • [ISO-abbreviation] J. Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ceramides; 0 / ceramide 1-phosphate; 3WHH0066W5 / Vanadates; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.138 / ceramide kinase; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 3.5.1.23 / Ceramidases; NGZ37HRE42 / Sphingosine
  •  go-up   go-down


31. Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, Ohmichi M, Testa JR, Kimura T: mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res; 2009 Sep 1;15(17):5404-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.
  • PURPOSE: Mammalian target of rapamycin (mTOR) plays a central role in cell proliferation and is regarded as a promising target in cancer therapy, including for ovarian cancer.
  • This study aimed to examine the role of mTOR as a therapeutic target in clear cell carcinoma of the ovary, which is regarded as an aggressive, chemoresistant histologic subtype.
  • EXPERIMENTAL DESIGN: Using tissue microarrays of 98 primary ovarian cancers (52 clear cell carcinomas and 46 serous adenocarcinomas), the expression of phospho-mTOR was assessed by immunohistochemistry.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2004 Jun;10(6):594-601 [15156201.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3):336-44 [18639330.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5853-7 [15208673.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):643-9 [15350353.001]
  • [Cites] Cancer Res. 1987 Jan 15;47(2):414-8 [3539322.001]
  • [Cites] J Biol Chem. 1998 Feb 27;273(9):5315-22 [9478990.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7418-26 [15534119.001]
  • [Cites] Cell. 2005 Mar 25;120(6):747-59 [15797377.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7052-8 [16103051.001]
  • [Cites] Mol Cancer Ther. 2005 Oct;4(10):1533-40 [16227402.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):52-6 [16445610.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1500-8 [16452206.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):71-5 [16290000.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1761-9 [16396982.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1369-74 [16641903.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):292-9 [16443261.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):285-91 [16516283.001]
  • [Cites] J Surg Oncol. 2006 Aug 1;94(2):138-43 [16847906.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1545-51 [16884363.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2584-9 [10861437.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5988-94 [11085518.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1862-8 [11280739.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9 [11504908.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2448-54 [12114452.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33490-500 [12087097.001]
  • [Cites] Mol Cell. 2003 Jun;11(6):1491-501 [12820963.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3194-200 [12860964.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):123-9 [14529671.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):252-61 [14729632.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):1013-23 [14871980.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23477-85 [15026414.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2408-13 [17363557.001]
  • [Cites] Oncogene. 2007 Mar 22;26(13):1932-40 [17001314.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):404-8 [17292461.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4261-70 [17634556.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3621-7 [17704411.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Autophagy. 2008 May;4(4):467-75 [18259115.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):197-203 [15262142.001]
  • (PMID = 19690197.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA06927; United States / NCI NIH HHS / CA / CA083638-10; United States / NCI NIH HHS / CA / CA077429-02; United States / NCI NIH HHS / CA / P30 CA006927-45; United States / NCI NIH HHS / CA / CA83638; United States / NCI NIH HHS / CA / R01 CA077429; United States / NCI NIH HHS / CA / P50 CA083638-10; United States / NCI NIH HHS / CA / P50 CA083638; United States / NCI NIH HHS / CA / R01 CA077429-02; United States / NCI NIH HHS / CA / CA77429; United States / NCI NIH HHS / CA / P30 CA006927
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 9HW64Q8G6G / Everolimus; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; Q20Q21Q62J / Cisplatin; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS125079; NLM/ PMC2743856
  •  go-up   go-down


32. Scott H, Griffin D: Ovarian cancer complicated by invasive pulmonary aspergillus. Gynecol Oncol; 2006 Jan;100(1):216-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer complicated by invasive pulmonary aspergillus.
  • CASE: A 59-year-old woman developed invasive pulmonary aspergillus after surgical debulking of an advanced ovarian adenocarcinoma and initiation of adjuvant combination chemotherapy.
  • CONCLUSION: Invasive pulmonary aspergillus is rarely diagnosed in patients with solid tumors such as ovarian cancer.
  • Successful treatment of the infection relies upon prompt diagnosis and utilization of effective antifungal medications for a prolonged period of time.
  • [MeSH-major] Aspergillosis / etiology. Cystadenocarcinoma, Serous / microbiology. Lung Diseases, Fungal / etiology. Ovarian Neoplasms / microbiology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169576.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Tassi RA, Bignotti E, Falchetti M, Ravanini M, Calza S, Ravaggi A, Bandiera E, Facchetti F, Pecorelli S, Santin AD: Claudin-7 expression in human epithelial ovarian cancer. Int J Gynecol Cancer; 2008 Nov-Dec;18(6):1262-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-7 expression in human epithelial ovarian cancer.
  • Claudin-7 (CLDN-7) is a tight junction protein recently found highly differentially expressed in ovarian carcinoma.
  • To evaluate its potential as a novel biomarker, in this study, we quantified and compared claudin-7 expression at messenger RNA and protein level in 110 patients harboring various histologic types of epithelial ovarian carcinomas (EOC).
  • CLDN-7 transcript was found significantly overexpressed in both primary and metastatic EOCs compared to normal human ovarian surface epithelium cell lines (fold change = 111.4, P < 0.001) by reverse transcription-polymerase chain reaction.
  • At the protein level, CLDN-7 expression was found significantly higher in tumors of primary and metastatic origin when compared to normal ovaries (P < 0.001), regardless of the histologic type, the grade of differentiation, and the pathologic stage of the disease (P = 0.12).
  • CLDN-7 is significantly overexpressed in all main histologic types of EOC and in single neoplastic cells disseminated in peritoneal cavity and pleural effusions, suggesting its potential role as novel diagnostic marker in ovarian cancer.
  • Despite widespread expression of CLDN-7 in several human normal tissues, the high density of CLDN-7 molecules, their membranous localization on EOC cells, and their lack of expression on the celomic epithelium in the peritoneal cavity suggest that this target could be potentially suitable for antibody-mediated localized therapies of ovarian adenocarcinoma.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / genetics. Membrane Proteins / metabolism. Ovarian Neoplasms / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298564.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN7 protein, human; 0 / Claudins; 0 / Membrane Proteins
  •  go-up   go-down


34. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, Lu KH: Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol; 2005 Mar;105(3):575-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for young premenopausal women with endometrial cancer.
  • OBJECTIVE: Endometrial cancer is the most common gynecologic malignancy in the United States.
  • The mean age at diagnosis is 61 years; however, 5-30% of women are aged younger than 50 years at the time of diagnosis.
  • METHODS: We conducted a retrospective cohort study of patients with histologically confirmed endometrial cancer treated at the University of Texas, M. D.
  • Anderson Cancer Center from 1989 to 2003.
  • Clinical characteristics including age, body mass index (BMI), parity, diabetes, and personal or family history of cancer were obtained from the medical record.
  • RESULTS: Twelve percent (188/1531) of all patients with endometrial adenocarcinoma were aged younger than 50 years.
  • The mean age at diagnosis was 41 years (range 21-49 years).
  • Thirty-six patients (19%) had synchronous ovarian cancers.
  • CONCLUSION: We found that the majority of patients diagnosed with endometrial cancer at a young age were obese and nulliparous.
  • In addition, we found a high incidence of synchronous primary ovarian cancers in this cohort of young, premenopausal women.
  • [MeSH-minor] Adenocarcinoma / etiology. Adult. Body Mass Index. Female. Humans. Menstruation Disturbances / complications. Middle Aged. Neoplasms, Multiple Primary / etiology. Neoplasms, Second Primary / etiology. Obesity / complications. Parity. Polycystic Ovary Syndrome / complications. Risk Factors

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15738027.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Saito N, Hatori T, Murata N, Shibuya K, Mitsuda A, Hasegawa C, Akima M, Ikawa M, Nonaka H: A case of concomitant occurrence of struma ovarii and malignant transformation of cystic teratoma. Int J Surg Pathol; 2007 Jul;15(3):318-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 77-year-old woman received a total abdominal hysterectomy and bilateral salpingo-oophorectomy because of a tumor in the left ovary.
  • The tumorous lesion of the cyst wall revealed a poorly differentiated adenocarcinoma.
  • The authors diagnosed that struma ovarii and other parats coexisted as a poorly differentiated adenocarcinoma that had arisen from a mature ovarian cystic teratoma.
  • As for the identification of the origin of adenocarcinomas arising from mature ovarian cystic teratomas, more cases need to be identified and investigated.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Ovarian Neoplasms / pathology. Struma Ovarii / pathology. Teratoma / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Keratin-7 / genetics. Keratin-7 / metabolism. Maximum Tolerated Dose

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17652549.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-7
  •  go-up   go-down


36. Kushida Y, Haba R, Kadota K, Doi T, Ishikawa M, Hirakawa E, Kira M: Composite mucinous and granulosa cell tumor of the ovary. Pathol Int; 2005 Dec;55(12):797-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite mucinous and granulosa cell tumor of the ovary.
  • A composite mucinous and granulosa cell tumor of the ovary in a 76-year-old woman is herein reported.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16287496.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


37. Goodheart MJ, Rose SL, Hattermann-Zogg M, Smith BJ, De Young BR, Buller RE: BRCA2 alteration is important in clear cell carcinoma of the ovary. Clin Genet; 2009 Aug;76(2):161-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRCA2 alteration is important in clear cell carcinoma of the ovary.
  • BRCA2 has been shown to play a significant role in hereditary ovarian carcinoma.
  • Several cases of clear cell carcinoma (CCC) of the ovary containing BRCA2 mutations have been identified.
  • We hypothesize that sequence variants of the BRCA2 gene are common in CCC of the ovary.
  • Multiple methods were utilized to detect BRCA2 genetic alterations in a cohort of 13 ovarian CCC.
  • Only one subject carried a germline sequence variation that might alter BRCA2 function despite the fact that a family history of breast, ovarian or colon cancer was common in this population.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. BRCA2 Protein / genetics. Mutation / genetics. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19656163.001).
  • [ISSN] 1399-0004
  • [Journal-full-title] Clinical genetics
  • [ISO-abbreviation] Clin. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / BRCA2 Protein
  •  go-up   go-down


38. Bolat F, Gumurdulu D, Erkanli S, Kayaselcuk F, Zeren H, Ali Vardar M, Kuscu E: Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma. Pathol Res Pract; 2008;204(6):379-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
  • Few studies have compared maspin with VEGF in ovarian carcinoma.
  • Therefore, we investigated the expression and correlation of maspin, VEGFA, VEGFC, and VEGFD with the tumorigenesis of the ovary and clinicopathologic variables.
  • Using immunohistochemistry, we examined maspin, VEGFA, VEGFC, and VEGFD expression in 60 ovarian carcinoma tissues (35 serous papillary carcinomas, 18 endometrioid carcinomas, and 7 primary ovarian mucinous carcinomas).
  • Maspin, VEGFC, and VEGFD are expressed in ovarian tumors with a poor prognostic parameters, and seem to play a role in ovarian cancer angiogenesis, progression, and lymph node metastases.
  • Our results indicate that in contrast to most other carcinomas, maspin expression is directly associated with the biological aggressiveness of ovarian carcinoma.
  • These results may offer new insights regarding the role of maspin in ovarian cancer and might also affect the diagnosis and treatment strategies.
  • [MeSH-major] Adenocarcinoma / metabolism. Ovarian Neoplasms / metabolism. Serpins / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor C / metabolism. Vascular Endothelial Growth Factor D / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343598.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SERPIN-B5; 0 / Serpins; 0 / VEGFA protein, human; 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D
  •  go-up   go-down


39. Ozbey C, Erdogan G, Pestereli HE, Simsek T, Karaveli S: Serous papillary adenocarcinoma and adult granulosa cell tumor in the same ovary. An unusual case. APMIS; 2005 Oct;113(10):713-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous papillary adenocarcinoma and adult granulosa cell tumor in the same ovary. An unusual case.
  • Surface epithelial-stromal cell tumors are the most common neoplasms of the ovary but occurrence of a serous adenocarcinoma and an adult granulosa cell tumor in the same ovary is an unusual incident.
  • In the present case report we describe this very uncommon occurrence in the ovary of a 50-year-old woman.
  • Microscopy revealed an adult granulosa cell tumor and a serous papillary adenocarcinoma in the left ovary.
  • Immunohistochemical staining with inhibin alpha and pancytokeratin confirmed the diagnosis.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] APMIS. 2007 Jun;115(6):769-71 [17550386.001]
  • (PMID = 16309432.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; 68238-35-7 / Keratins
  •  go-up   go-down


40. Silva RG, Dahmoush L, Gerke H: Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. JOP; 2006;7(1):66-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy.
  • CONTEXT: Malignant mixed Mullerian tumors are rare ovarian neoplasms that account for less than 2% of ovarian malignancies.
  • CASE REPORT: We describe a 69-year-old female with concomitant Duke's C adenocarcinoma of the colon and stage III-C malignant mixed Mullerian tumor that presented with malignant ascites, increasing abdominal girth and a pancreatic head mass.
  • The tumor was morphologically identical to the surgical specimen of her ovarian mass.
  • Although ovarian adenocarcinoma has been reported as a primary site of pancreatic metastasis, it has not been previously described originating from a mixed Mullerian tumor of the ovary presenting as a cystic pancreatic head mass.
  • [MeSH-major] Mixed Tumor, Mullerian / secondary. Ovarian Neoplasms / pathology. Pancreatic Neoplasms / secondary


41. Dhakal HP, Pradhan M: Histological pattern of gynecological cancers. JNMA J Nepal Med Assoc; 2009 Oct-Dec;48(176):301-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The information on cancer incidence is an important basis to prioritize the preventive policy of a country.
  • METHODS: A retrospective analysis was performed in histopathologically proven gynecological malignancies by retrieving data from the archives of the Department of Pathology, BP Koirala Memorial Cancer Hospital between July 1999 and April 2004.
  • RESULTS: Out of total 1517 cases of gynecological cancers diagnosed, 1293 cases (85.23%) were cervical, 97 (6.39%) ovarian, 48 (3.16%) vulval, 41 (2.7%) vaginal, 32 (2.11%) endometrial cancers as well as 5 (0.33%) choriocarcinoma and 1 (0.07%) fallopian tube cancer.
  • Squamous cell carcinoma was the commonest histologic type in cervical, vaginal and vulval cancers whereas serous adenocarcinoma and endometrioid adenocarcinoma were commonest histological types in the ovary and endometrium respectively.
  • CONCLUSIONS: Cervical cancer is the most frequent gynecological malignancy in Nepal.
  • Since it is a preventable disease, national screening and awareness programs are necessary to reduce the burden of the cancer and to improve the health of women in Nepal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21105554.001).
  • [ISSN] 0028-2715
  • [Journal-full-title] JNMA; journal of the Nepal Medical Association
  • [ISO-abbreviation] JNMA J Nepal Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


42. Jiang J, Chen W, Zhuang R, Song T, Li P: The effect of endostatin mediated by human mesenchymal stem cells on ovarian cancer cells in vitro. J Cancer Res Clin Oncol; 2010 Jun;136(6):873-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of endostatin mediated by human mesenchymal stem cells on ovarian cancer cells in vitro.
  • To investigate the impact of secreted endostatin on cancer cells, SKOV3 cells were co-cultured with MSC-EN cells in Millicell for 48 h, then apoptosis and cell cycle were analyzed on a flow cytometer.
  • CONCLUSION: We found that MSCs possessed great migratory capacity in vitro and the human ovarian adenocarcinoma cell line SKOV3 could significantly induce the migration of MSCs.
  • [MeSH-major] Adenocarcinoma / therapy. Angiogenesis Inhibitors / pharmacology. Apoptosis / drug effects. Endostatins / pharmacology. Genetic Therapy / methods. Mesenchymal Stromal Cells. Ovarian Neoplasms / therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2004 Nov;25(5):1267-71 [15492814.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3792-803 [12228199.001]
  • [Cites] Nat Med. 2004 Aug;10(8):858-64 [15235597.001]
  • [Cites] Acta Oncol. 2004;43(2):175-81 [15163166.001]
  • [Cites] Science. 2003 Jul 25;301(5632):452-4 [12881543.001]
  • [Cites] Cancer Biol Ther. 2003 Jan-Feb;2(1):48-52 [12673115.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1669-75 [14576065.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3601-8 [18818971.001]
  • [Cites] Int J Hematol. 2007 Jul;86(1):8-16 [17675260.001]
  • [Cites] FASEB J. 2007 Oct;21(12):3153-61 [17513560.001]
  • [Cites] Nat Med. 2003 Jun;9(6):702-12 [12778169.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3603-8 [12097260.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Gene Ther. 2005 Jan;12(1):30-8 [15550927.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11917-23 [13679583.001]
  • [Cites] Int J Gynecol Cancer. 2000 Jan;10(S1):33-37 [11240730.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Chin Med J (Engl). 2005 Feb 20;118(4):296-301 [15740667.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4319-28 [16618757.001]
  • [Cites] J Neurosci Res. 2000 Aug 15;61(4):364-70 [10931522.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6 Suppl 12):S25-6 [17223447.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):496-507 [15563312.001]
  • [Cites] J Cell Sci. 2005 Oct 1;118(Pt 19):4343-52 [16144866.001]
  • [Cites] Int J Exp Pathol. 2002 Dec;83(6):265-74 [12657135.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):594-607 [16376330.001]
  • [Cites] APMIS. 2003 Nov;111(11):1011-8 [14629267.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3772-84 [12228197.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7669-74 [11606410.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3967-79 [15899784.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Hematology. 2002 Apr;7(2):113-7 [12186702.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1835-42 [15014038.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1118-27 [15902288.001]
  • [Cites] Circulation. 2002 Jan 1;105(1):93-8 [11772882.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2396-402 [11588036.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1290-8 [16731762.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1259-67 [15709197.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 3;96(21):1593-603 [15523088.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5789-97 [17575146.001]
  • [Cites] Science. 1999 Apr 2;284(5411):143-7 [10102814.001]
  • [Cites] Gynecol Obstet Invest. 2000;50(4):269-74 [11093052.001]
  • [Cites] Life Sci. 2005 Aug 5;77(12):1331-40 [15936041.001]
  • [Cites] Hum Gene Ther. 2003 Jul 1;14(10):997-1008 [12869217.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3307-18 [15833864.001]
  • [Cites] J Orthop Sci. 2007 Nov;12(6):562-7 [18040639.001]
  • [Cites] Adv Cancer Res. 2005;94:197-229 [16096002.001]
  • (PMID = 19921255.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Endostatins
  •  go-up   go-down


43. Yu KJ, Lee HE, Ho HC, Lee JC, Chang JW, Hong HS, Yang CH: Carcinoma erysipelatoides from squamous cell carcinoma of unknown origin. Int J Clin Pract; 2005 Sep;59(9):1104-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is frequently observed in patients with breast carcinoma as well as adenocarcinoma of pancreas, rectum, lung, ovary and parotid gland.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115190.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 13
  •  go-up   go-down


44. Liscovitch M, Ravid D: A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett; 2007 Jan 8;245(1-2):350-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells.
  • Multidrug-resistant MCF-7 breast adenocarcinoma cells (originally named MCF-7/AdrR cells and later re-designated NCI/ADR-RES) have served as an important and widely used research tool during the last two decades.
  • The results of these analyses, recently posted on the Web, show that NCI/ADR-RES cells are derived from OVCAR-8 ovarian adenocarcinoma cells.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Antibiotics, Antineoplastic / pharmacology. Cell Line, Tumor. Clone Cells / metabolism. Female. Gene Expression Profiling. Humans. Mutation. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Tumor Suppressor Protein p53 / genetics


45. Misir A, Sur M: Sertoliform endometrioid carcinoma of the ovary: a potential diagnostic pitfall. Arch Pathol Lab Med; 2007 Jun;131(6):979-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoliform endometrioid carcinoma of the ovary: a potential diagnostic pitfall.
  • Sertoliform endometrioid carcinoma of the ovary (SEC) is an uncommon variant that bears histologic similarity to Sertoli and Sertoli-Leydig cell tumors (SLTs).
  • Based on the clinicopathologic behavior of this entity, SEC should be considered a well-differentiated carcinoma with relatively good prognosis if limited to the ovary.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Diagnostic Errors / prevention & control. Ovarian Neoplasms / pathology. Sertoli Cell Tumor / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adult. Aged. Carcinoid Tumor / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Krukenberg Tumor / diagnosis. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550331.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Voglmayr E, Widder J: [Who makes decisions--the dilemma of decision-making within the framework of job-sharing in a hospital]. Wien Med Wochenschr; 2006 May;156(9-10):314-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was receiving immunosuppressive therapy after kidney transplantation and then suffered from a carcinomatous ovary.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Communication. Decision Making. Endometrial Neoplasms / therapy. Interprofessional Relations. Neoplasms, Multiple Primary / therapy. Ovarian Neoplasms / therapy. Palliative Care / methods. Patient Care Team. Urinary Bladder Neoplasms / secondary. Urinary Bladder Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Health Care Philos. 2003;6(3):235-46 [14620460.001]
  • (PMID = 16830254.001).
  • [ISSN] 0043-5341
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  •  go-up   go-down


47. Christie DR, Shaikh FM, Lucas JA 4th, Lucas JA 3rd, Bellis SL: ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function. J Ovarian Res; 2008 Oct 01;1(1):3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function.
  • BACKGROUND: Ovarian adenocarcinoma is not generally discovered in patients until there has been widespread intraperitoneal dissemination, which is why ovarian cancer is the deadliest gynecologic malignancy.
  • Our laboratory has previously shown that the Golgi glycosyltransferase, ST6Gal-I, mediates the hypersialylation of beta1 integrins in colon adenocarcinoma, which leads to a more metastatic tumor cell phenotype.
  • Interestingly, ST6Gal-I mRNA is known to be upregulated in metastatic ovarian cancer, therefore the goal of the present study was to determine whether ST6Gal-I confers a similarly aggressive phenotype to ovarian tumor cells.
  • METHODS: Three ovarian carcinoma cell lines were screened for ST6Gal-I expression, and two of these, PA-1 and SKOV3, were found to produce ST6Gal-I protein.
  • CONCLUSION: ST6Gal-I mediated sialylation of beta1 integrins in ovarian cancer cells may contribute to peritoneal metastasis by altering tumor cell adhesion and migration through extracellular matrix.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2005;69(5):436-44 [16319516.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):67-75 [11206841.001]
  • [Cites] Clin Exp Metastasis. 2004;21(8):685-97 [16035613.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4645-52 [15930282.001]
  • [Cites] Glycobiology. 1999 Oct;9(10):1003-8 [10521536.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2253-9 [9605774.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):362-7 [10366461.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5722-7 [10318951.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1525-37 [10329605.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):243-7 [10188726.001]
  • [Cites] Oncology. 1999;56(2):89-96 [9949292.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4066-70 [9751611.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1997;254(9-10):437-41 [9438113.001]
  • [Cites] Biochim Biophys Acta. 1998 Jan 8;1379(1):23-8 [9468328.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4249-56 [9331085.001]
  • [Cites] FEBS Lett. 1997 Jun 16;409(3):347-50 [9224687.001]
  • [Cites] Int J Cancer. 1996 Sep 17;67(6):826-30 [8824555.001]
  • [Cites] J Biol Chem. 1994 Apr 8;269(14):10637-43 [8144653.001]
  • [Cites] Eur J Biochem. 1993 Jan 15;211(1-2):135-40 [7678804.001]
  • [Cites] Glycobiology. 1992 Feb;2(1):49-56 [1550989.001]
  • [Cites] J Biol Chem. 1990 Oct 15;265(29):17849-53 [2211665.001]
  • [Cites] Br J Cancer. 1991 Oct;64(4):617-20 [1911209.001]
  • [Cites] Eur J Biochem. 2004 Sep;271(18):3623-34 [15355339.001]
  • [Cites] Biochim Biophys Acta. 2004 May 27;1663(1-2):52-60 [15157607.001]
  • [Cites] Oncogene. 2003 Oct 16;22(46):7137-45 [14562042.001]
  • [Cites] Hybridoma. 2000 Aug;19(4):281-6 [11001400.001]
  • [Cites] Mol Cell Biol Res Commun. 2000 Jan;3(1):48-52 [10683317.001]
  • [Cites] Glycobiology. 2007 Dec;17(12):1344-56 [17884841.001]
  • [Cites] Lab Invest. 2007 Sep;87(9):851-7 [17632542.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):369-75 [16428474.001]
  • [Cites] World J Gastroenterol. 2005 Nov 14;11(42):6701-6 [16425369.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):395-401 [12798701.001]
  • [Cites] Clin Exp Metastasis. 2003;20(2):143-52 [12705635.001]
  • [Cites] Med Res Rev. 2003 Jan;23(1):32-47 [12424752.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):32830-6 [12091385.001]
  • [Cites] Exp Cell Res. 2002 May 15;276(1):101-10 [11978012.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2071-80 [11733357.001]
  • [Cites] Biochim Biophys Acta. 2001 May 31;1536(2-3):148-60 [11406350.001]
  • [Cites] Glycoconj J. 2000 Oct;17(10):669-76 [11425186.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):631-9 [16112178.001]
  • (PMID = 19014651.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA084248
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2584051
  •  go-up   go-down


48. Zhang J, Li YL, Zhou CY, Hu YT, Chen HZ: Expression of octamer-4 in serous and mucinous ovarian carcinoma. J Clin Pathol; 2010 Oct;63(10):879-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of octamer-4 in serous and mucinous ovarian carcinoma.
  • AIMS: To assess the expression of Oct4 in epithelial ovarian tumours.
  • METHODS: Expression of Oct4 was evaluated by immunohistochemistry in 460 cases of various epithelial ovarian lesions as well as 35 cases of normal fallopian tube epithelium.
  • RESULTS: Oct4 expression was significantly increased from normal epithelium (both ovarian epithelium and fallopian tube epithelium) to benign and borderline cystadenoma to carcinoma in the serous lesion subgroup.
  • Oct4 overexpression was associated with more advanced FIGO stage and higher histological grade in serous adenocarcinoma.
  • Conversely, Oct4 expression did not differ among mucinous lesions or correlate with clinicopathological parameters in patients with mucinous adenocarcinoma.
  • CONCLUSION: Results suggest that Oct4 expression may contribute to the initiation, promotion and progression of serous ovarian carcinoma; it might be a useful biomarker for the diagnosis and outcome prediction of serous ovarian carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cystadenoma / metabolism. Octamer Transcription Factor-3 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Disease Progression. Epithelium / metabolism. Fallopian Tubes / metabolism. Female. Humans. Neoplasm Proteins / metabolism. Neoplasm Staging. Ovary / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876318.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human
  •  go-up   go-down


49. Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, Brown J, Gershenson DM, Ramirez PT: Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol; 2010 Aug;116(2 Pt 1):269-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary.
  • OBJECTIVE: To estimate the prevalence of lymph node involvement in women with primary mucinous ovarian carcinomas.
  • METHODS: A retrospective study was performed of patients with primary mucinous ovarian carcinomas evaluated at a single institution between 1985 and 2007.
  • Patients with tumors of low malignant potential and mucinous carcinomas metastatic to the ovary from other primary sites were excluded.
  • RESULTS: Patients with primary mucinous ovarian carcinomas were identified (n=107).
  • At time of surgery, 93 patients (87%) had tumors that grossly appeared to be confined to the ovary, and 14 patients (13%) had evidence of extraovarian disease.
  • Of the 93 patients with tumors that grossly appeared to be confined to the ovary at surgical exploration, 51 (55%) underwent lymphadenectomy (n=27 pelvic and paraaortic, n=19 pelvic only, n=5 paraaortic only).
  • CONCLUSION: There were no cases of isolated lymph node metastases among women with primary mucinous carcinoma grossly confined to the ovary, suggesting that routine lymphadenectomy may be omitted in these patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Lymph Nodes / pathology. Ovarian Neoplasms / pathology


50. Kawagishi N, Shirahata Y, Ishida K, Satoh K, Enomoto Y, Akamatsu Y, Sekiguchi S, Fukumori T, Fujimori K, Satoh A, Moriya T, Satomi S: Hepatic resection of giant metastatic tumor from clear cell carcinoma of the ovary. J Hepatobiliary Pancreat Surg; 2005;12(2):155-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection of giant metastatic tumor from clear cell carcinoma of the ovary.
  • All cancer patients, particularly those treated for colorectal cancer, should be monitored for the presence of liver metastases, but liver metastases from ovarian clear cell carcinoma are quite rare.
  • We report a patient subjected to extended left hepatectomy due to a giant metastasis 5 years after surgical treatment for an ovarian neoplasm that was histopathologically diagnosed as clear cell carcinoma.
  • A 58-year-old woman had undergone hysterectomy and bilateral salpingo-oophorectomy due to ovarian cancer (stage Ic).
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / secondary. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868082.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement